The Protocole
RETATRUTIDE 16mg
Back
SINGLE PEPTIDE

RETATRUTIDE 16mg

Triple Agonist

GLP-1
GIP
GLUCAGON

An advanced, once-weekly injectable peptide that activates three metabolic pathways — GLP-1, GIP, and glucagon — to accelerate fat loss and improve metabolic efficiency.

$445.00
1

Ships cold-chain. Once-weekly subcutaneous injection. Use under physician guidance.

RETATRUTIDE (16mg)

Triple Agonist

GLP-1
GIP
GLUCAGON

About

Retatrutide is an advanced, once-weekly injectable peptide that activates three key metabolic pathways - GLP-1, GIP, and glucagon receptors - to accelerate fat loss, enhance insulin sensitivity, and improve metabolic efficiency. Often described as the "next-generation GLP-1," it optimizes glucose control while uniquely boosting energy expenditure and lean-mass preservation. Note: Physical label displays 4mg/0.5ml in a 2ml vial size, for a total content of 16mg.

Mechanism of Action

MECHANISM OF ACTION

By simultaneously stimulating the GLP-1, GIP, and glucagon receptors, Retatrutide reduces appetite, improves insulin secretion, enhances glucose uptake, and increases basal metabolic rate. The triple agonism results in greater calorie burn and fat oxidation compared with single- or dual-pathway peptides, supporting powerful body-recomposition outcomes.

Benefits

Marked reduction in body fat and waist circumference
Improved blood-sugar and insulin balance
Enhanced energy expenditure and fat oxidation
Preserved lean-muscle mass during weight loss
Sustained appetite control and metabolic regulation

Expected Effects & Timeline

Week 1-2

Reduced appetite, steadier blood-sugar levels, lighter digestion

Week 4-6

Noticeable fat loss, improved energy, mild body recomposition

Week 8-12

Significant weight and fat percentage reduction, improved endurance

Long term

Continued fat-loss stabilization, optimized metabolism, cardiometabolic resilience

Dosing Instructions

BASELINE DOSE

12.5 units (1mg) per injection, 1x/per week

INJECTION SITE

Subcutaneous fat (abdomen). Rotate sites to avoid irritation.

TIME OF DAY

Anytime of day

Titrating above 1mg per week should be under the guidance of a physician. If you would like to request a physician consultation, email concierge@theprotocole.com

Vial Details

Total Content

Retatrutide (16mg)

Concentration

4mg/0.5ml (8mg/ml)

Vial Size

2ml

Supply

16 weeks

Storage

Refrigerate at 36–46°F (2–8°C). Do not freeze.

Recommended Cycle

CYCLE

3 months on, 1 month off; Repeat up to 3 cycles annually or as clinically indicated

Potential Side Effects

  • Mild nausea or constipation during initial weeks
  • Decreased appetite or early satiety
  • Occasional fatigue as body adjusts
  • Vomiting or delayed gastric emptying (rare)

Contraindications

  • Active cancer
  • Pregnancy or breastfeeding
  • Known hypersensitivity to any peptide components

Important Note

This therapy should be used under the guidance of a healthcare provider. If you experience any of the following, discontinue use and contact us immediately:

  • Severe abdominal pain, persistent vomiting, or signs of pancreatitis
  • GI symptoms prevent adequate hydration or nutrition
  • Severe swelling or injection site reaction
  • Fever >100.4°F (38°C)
  • Fatigue that worsens over time
  • Severe nausea, rash, dizziness, or hives
  • Shortness of breath, chest tightness, or facial swelling